LEADER 00000nam a22005173i 4500
001 EBC1574351
003 MiAaPQ
005 20200713055255.0
006 m o d |
007 cr cnu||||||||
008 200713s2014 xx o ||||0 eng d
020 9781118590614|q(electronic bk.)
020 |z9780470621882
035 (MiAaPQ)EBC1574351
035 (Au-PeEL)EBL1574351
035 (CaPaEBR)ebr10814726
035 (CaONFJC)MIL548134
035 (OCoLC)864746032
040 MiAaPQ|beng|erda|epn|cMiAaPQ|dMiAaPQ
050 4 RC280.S5.D476 2014eb
082 0 616.99/477
100 1 Lacouture, Mario E
245 10 Dermatologic Principles and Practice in Oncology :
|bConditions of the Skin, Hair, and Nails in Cancer
Patients
250 1st ed
264 1 Somerset :|bJohn Wiley & Sons, Incorporated,|c2014
264 4 |c©2013
300 1 online resource (442 pages)
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
505 0 Cover -- Title page -- Copyright page -- Contents -- List
of Contributors -- Preface -- 1: Dermatology and Oncology
-- 1: Epidemiology and Burden of Disease -- Introduction -
- Dermatologic health in cancer patients and survivors --
Financial burden -- Health-related quality of life --
Dosing of chemotherapy -- Conclusions -- References --
Appendix 1.1 Anticancer agents and associated adverse
events affecting the skin, mucosa, hair, and nails. Based
on data from Litt JZ, 2009 [8]. -- 2: The History of
Supportive Oncodermatology -- Evolution of anticancer
therapeutics -- Spectrum of dermatologic adverse events
stemming from conventional cytotoxic chemotherapy agents -
- Radiation and surgery-induced mucocutaneous toxicities -
- Mucocutaneous toxicities induced by novel targeted
agents -- Emergence of supportive oncodermatology and
future directions -- References -- 3: Structure and
Function of the Integumentary System and the Dermatology
Lexicon -- Introduction -- Skin -- Epidermis -- Dermal-
epidermal junction -- Dermis -- Vasculature -- Nerves --
Subcutaneous tissue -- Appendages -- Eccrine sweat glands
-- Apocrine sweat glands -- Sebaceous glands -- Hair --
Nails -- Morphology -- Raised lesions -- Papule -- Plaque
-- Nodule -- Cyst -- Wheal -- Depressed lesions -- Erosion
-- Ulcer -- Atrophy -- Poikiloderma -- Flat lesions --
Macule -- Patch -- Sclerosis -- Erythema -- Erythroderma -
- Fluid-filled lesions -- Vesicle and bulla -- Pustule --
Furuncle -- Abscess -- Surface changes -- Scale -- Crust -
- Eschar -- Purpura and vascular lesions -- Purpura --
Infarct -- Shape, configuration, arrangement, and
distribution of lesions -- Conclusions -- 4: Types of
Dermatologic Reactions -- Exanthematous eruptions --
Urticarial eruptions -- Lichenoid eruptions -- Acneiform
eruptions -- Pustular eruptions (acute generalized
exanthematous pustulosis)
505 8 Bullous eruptions -- Drug-induced vasculitis --
Erythroderma -- Approach to patients with suspected drug
eruption -- Step 1: Recognizing the morphology -- Step 2:
Associated symptoms and systemic involvement -- Step 3:
Histopathologic assessment -- Step 4: Determining the
offending drug -- Conclusions -- References -- 5: Grading
Dermatologic Adverse Events in Clinical Trials Using CTCAE
v4.0 -- Common Terminology Criteria for Adverse Events --
CTCAE grade scale -- Attribution -- Changes in CTCAE V4.0
-- Refined grading to correlate with clinical management -
- Alopecia -- Rash acneiform -- Skin hyperpigmentation --
Split of embedded terms -- Rash maculopapular --
Erythroderma -- Bullous dermatitis -- Nail discoloration,
nail ridging, and nail loss -- New adverse events --
Hypertrichosis -- Hypohidrosis -- Lipohypertrophy --
Periorbital edema -- Moved to different SOC --
Papulopustular rash -- Rash pustular -- Paronychia --
CTCAE vs. MESTT -- Conclusions -- References -- 6:
Psychosocial Issues in Oncology: Clinical Management of
Psychosocial Distress, Health-Related Quality of Life, and
Special Considerations in Dermatologic Oncology --
Psychosocial distress -- Distress among dermatologic
samples -- Dermatologic AEs from cancer treatment -- Risk
factors for distress -- Clinical management of distress --
Measuring distress and health-related quality of life in
dermatologic oncology -- Psychosocial interventions in
oncodermatology -- Conclusions -- References -- 7:
Dermatopathology -- Introduction -- Mucocutaneous
neoplasms -- Solar (actinic) keratosis -- Squamous cell
carcinoma -- Melanocytic tumors -- Inflammatory dermatoses
-- Interface (lichenoid) dermatitis -- Spongiotic
dermatitis -- Superficial or superficial and deep
perivascular lymphohistiocytic inflammation -- Suppurative
and granulomatous dermatitis -- Conclusions -- References
505 8 2: Cancer-Related Dermatologic Disorders -- 8:
Paraneoplastic, Inherited Cancer Syndrome, and
Environmental Carcinogen-Related Dermatoses --
Paraneoplastic disorders -- Skin changes from hormone-
secreting tumors -- Ectopic ACTH-producing tumors --
Proliferative and inflammatory paraneoplastic dermatoses -
- Inherited syndromes with increased cancer risk and skin
effects -- Muir-Torre syndrome -- Gardner syndrome --
Cowden syndrome -- Peutz-Jeghers syndrome -- Birt-Hogg-
Dubé -- Howel-Evans syndrome -- Hereditary leiomyomatosis/
renal cell cancer syndrome -- Environmental carcinogens
with increased cancer risk and skin effects -- Arsenic --
Vinyl chloride -- Ionizing radiation -- References -- 3:
Dermatologic Conditions During Cancer Therapy -- 9: Oral
Mucosal Complications of Cancer Therapy -- Introduction --
Mucosal injury attributable to cytotoxic therapy --
Clinical features and course of mucositis -- Mucositis
scoring -- Clinician-based scoring -- Toxicity description
and assessment -- Patient management scales -- Research-
directed scales -- Variability between mucositis scales --
Patient-reported instruments to assess mucositis severity
-- Minimizing inter-observer variability in mucositis
assessment -- Impact of mucositis -- Pathobiology of
mucositis -- Signal amplification -- Risk factors for
mucositis -- The oral environment and mucositis -- Status
of the development of therapies for mucositis -- Mucosal
changes associated with targeted therapies -- Mucosal
injury associated with mTOR inhibitors -- Small molecules
and antibodies -- Oral manifestations of graft versus host
disease -- Conclusions -- References -- 10: Hair Disorders
Associated with Anticancer Agents -- Introduction -- Basic
hair anatomy and function -- Types of chemotherapy-induced
hair loss/alopecia -- Telogen effluvium -- Anagen
effluvium -- Abnormal hair growth
505 8 Permanent chemotherapy-induced alopecia -- Radiation-
induced alopecia -- Grading scales utilized for
determining degree of hair loss or regrowth -- Potential
treatments for chemotherapy-induced alopecia -- Prevention
of hair loss -- Acceleration of regrowth after
chemotherapy -- Conclusions -- References -- 11: Nail
Abnormalities in Oncology Practice -- Introduction --
Drugs -- Classic cytotoxic drugs -- Epidermal growth
factor receptor inhibitors -- Symptoms -- Nail matrix and
nail plate alterations -- Nail fold involvement -- Nail
bed involvement -- Digit tip xerosis -- Classification --
Treatment -- Prevention -- Conclusions -- References -- 12
: Pruritus -- Introduction -- Cutaneous diseases --
Systemic and psychiatric diseases -- Malignancy -- Therapy
-- Clinical findings -- Visual analog scale for pruritus -
- Management -- General principles -- Topical treatments -
- Systemic treatments -- Physical treatments --
Phototherapy -- Bio-behavioral therapy -- Conclusions --
References -- 13: Management Options for Hot Flashes in
Cancer Patients -- Introduction -- Grading of hot flashes
-- Treatment of hot flashes -- Pharmacologic interventions
-- Nonpharmacologic interventions -- Behavioral therapies
-- Physical measures -- Conclusions and recommendations --
References -- 4: Skin Toxicities to Chemotherapy -- 14:
Alkylating Agents -- Introduction -- Nitrogen mustards --
Mustargen (mechlorethamine) -- Cyclophosphamide --
Ifosfamide -- Melphalan -- Chlorambucil -- Aziridines and
epoxides -- ThioTEPA -- Mitomycin C -- Alkyl sulfonates --
Busulfan -- Nitrosoureas -- Carmustine
(bischloroethylnitrosourea) -- Streptozocin -- Hydrazines
and triazine derivatives -- Procarbazine -- Dacarbazine --
Temozolomide -- Hydroxurea -- References -- 15:
Antimetabolite Reactions -- Introduction -- Methotrexate -
- Pemetrexed -- Capecitabine -- Cytarabine -- Gemcitabine
505 8 Mercaptopurine -- Thioguanine -- Fludarabine -- Cladribine
-- References -- 16: Topoisomerase-Interacting Agents --
Introduction -- Topoisomerase I inhibitors -- Irinotecan
and topotecan -- Topoisomerase II inhibitors --
Anthracyclines: Doxorubicin, liposomal doxorubicin,
epirubicin and idarubicin -- Etoposide and teniposide --
Mitoxantrone -- Alopecia -- Hand-foot syndrome --
Hyperpigmentation -- Intertrigo -- Nail changes --
Extravasation of topoisomerase inhibitors -- Stevens-
Johnson syndrome -- Mucositis -- Radiation recall --
References -- 17: Epidermal Growth Factor Receptor
Inhibitor Reactions -- Introduction -- Epidermal growth
factor receptor inhibitors -- Dermatologic adverse events
of EGFRIs -- Papulopustular (acneiform) rash -- Xerosis
and pruritus -- Hyperpigmentation -- Telangiectasias --
Mucosal toxicities -- Hair alterations -- Nail and
periungual involvement -- Interaction of EGFRIs with
conventional cytotoxic chemotherapy and radiotherapy --
Conclusions -- References -- 18: Small Molecule
Multikinase Inhibitors -- Introduction -- Kit, PDGFR and
bcr-abl inhibitors: imatinib, nilotinib, dasatinib --
Drugs, indications, and mechanisms of action --
Antiangiogenic agents: sorafenib, sunitinib axitinib,
regorafenib, and pazopanib -- Hand-foot skin reaction --
Subungual splinter hemorrhages -- Erythematous rashes --
Hair modifications -- Xerosis -- Genital involvement --
Mucositis -- AEs specifically related to sunitinib -- AEs
related specifically to sorafenib -- mTOR inhibitors:
everolimus and temsirolimus -- Drugs and mechanisms of
action -- Skin manifestations -- Conclusions -- References
-- 19: Antimicrotubule Agents -- Introduction -- Taxanes -
- Clinical features -- Treatment of choice and prognosis -
- Vinca alkaloids -- Clinical features -- Treatment of
choice and prognosis -- Estramustine phosphate sodium --
References
505 8 20: Histone Deacetylase Inhibitors, Proteasome Inhibitors,
Demethylating Agents, Arsenicals, and Retinoids
520 List of Contributors, vii Preface, x Section 1
Dermatology and Oncology 1 Epidemiology and Burden of
Disease, 3Beth N. McLellan, Devika Patel and Mario E.
Lacouture 2 The History of Supportive Oncodermatology,
17Yevgeniy Balagula, Steven T. Rosen and Mario E.
Lacouture 3 Structure and Function of the Integumentary
System and the Dermatology Lexicon, 24Emmy Graber and Amit
Garg 4 Types of Dermatologic Reactions, 33Raed O.
Alhusayen, Sandra R. Knowles and Neil H. Shear 5 Grading
Dermatologic Adverse Events in Clinical Trials Using CTCAE
v4.0, 47Alice Chen, Asha Acharya and Ann Setser 6
Psychosocial Issues in Oncology: Clinical Management of
Psychosocial Distress, Health-Related Quality of Life, and
Special Considerations in Dermatologic Oncology, 60Lynne
I. Wagner and David Cella 7 Dermatopathology, 69Molly A.
Hinshaw and James L. Troy Section 2 Cancer-Related
Dermatologic Disorders 8 Paraneoplastic, Inherited
Cancer Syndrome, and Environmental Carcinogen-Related
Dermatoses, 77Cindy England Owen and Jeffrey P. Callen
Section 3 Dermatologic Conditions During Cancer Therapy
9 Oral Mucosal Complications of Cancer Therapy, 89Stephen
T. Sonis 10 Hair Disorders Associated with Anticancer
Agents, 100Caroline Yeager and Elise A. Olsen 11 Nail
Abnormalities in Oncology Practice, 115Robert Baran,
Bernard Fouilloux and Caroline Robert 12 Pruritus,
122Tejesh Patel and Gil Yosipovitch 13 Management
Options for Hot Flashes in Cancer Patients, 131Amanda R.
Moraska and Charles L. Loprinzi Section 4 Skin
Toxicities to Chemotherapy 14 Alkylating Agents,
147Elisabeth Livingstone, Lisa Zimmer, Larissa Leister and
Dirk Schadendorf 15 Antimetabolite Reactions, 160Emily
Y. Chu and Heidi H. Kong 16 Topoisomerase-Interacting
Agents, 170Tomas Skacel, Roger von Moos and Reinhard
Dummer 17 Epidermal Growth Factor Receptor Inhibitor
520 8 Reactions, 184Yevgeniy Balagula and Mario E. Lacouture
18 Small Molecule Multikinase Inhibitors, 196Caroline
Robert, Vincent Sibaud and Christine Mateus 19
Antimicrotubule Agents, 208Claus Garbe 20 Histone
Deacetylase Inhibitors, Proteasome Inhibitors,
Demethylating Agents, Arsenicals, and Retinoids, 215Najla
Al-Dawsari, Shannon C. Trotter and Francine Foss 21
Miscellaneous Reactions, 224Katharina C. Kaehler,
Christine B. Boers-Doets, Mario E. Lacouture and Axel
Hauschild 22 Skin Toxicities due to Biotherapy,
233Kathryn T. Ciccolini, Katharina C. Kaehler, Mario E.
Lacouture and Axel Hauschild 23 Monoclonal Antibodies,
241Caroline Robert 24 Endocrine Agents, 248Katherine
Szyfelbein Masterpol, Maura Dickler and Mario E. Lacouture
25 Agents for the Management of Hematologic Reactions,
257Mee-young Lee and Caroline C. Kim 26 Radiation-
Induced Skin Reactions, 264Rebecca K.S. Wong and Zahra
Kassam 27 Hematopoietic Stem Cell Transplantation and
Graft Versus Host Disease, 281Stephanie W. Hu and Jonathan
Cotliar 28 Extravasation Reactions, 295Seppo W. Langer
29 Topical Anticancer Therapies, 301Patricia L. Myskowski
30 Life-threatening (Serious) Dermatologic Adverse Events,
310Milan J. Anadkat 31 Dermatologic Infections,
319Yevgeniy Balagula, Mario E. Lacouture and James I. Ito
Section 5 Late Cutaneous Events from Cancer Treatment 32
Late Dermatologic Conditions, 339Jennifer Nam Choi
Section 6 Dermatologic Practice in Oncology 33
Management Algorithms for Dermatologic Adverse Events,
367Alyx Rosen, Iris Amitay-Laish and Mario E. Lacouture
34 Dermatologic Therapeutics and Formulations, 384Judy H.
Borovicka, Jennifer R.S. Gordon, Ann Cameron Haley, Nicole
E. Larsen and Dennis P. West 35 Dermatologic Techniques
and Procedures, 401Robert Eilers Jr., Kishwer S. Nehal and
Erica H. Lee 36 Appearance-Related Concerns in the
520 8 Cancer Patient, 410Amy J. Derick Index, 417
588 Description based on publisher supplied metadata and other
sources
590 Electronic reproduction. Ann Arbor, Michigan : ProQuest
Ebook Central, 2020. Available via World Wide Web. Access
may be limited to ProQuest Ebook Central affiliated
libraries
650 0 Skin -- Diseases -- Etiology.;Skin -- Diseases --
Psychology.;Tumors -- Complications
655 4 Electronic books
776 08 |iPrint version:|aLacouture, Mario E.|tDermatologic
Principles and Practice in Oncology : Conditions of the
Skin, Hair, and Nails in Cancer Patients|dSomerset : John
Wiley & Sons, Incorporated,c2014|z9780470621882
856 40 |uhttps://ebookcentral.proquest.com/lib/sinciatw/
detail.action?docID=1574351|zClick to View
